True polycythaemia (with a raised red cell mass) can be classified in terms of normal or increased levels of the glycoprotein hormone erythropoietin, since the latter has been shown to playa key part in the control of erythropoiesis. Primary polycythaemia is a J generalized myeloproliferative disease where the control mechanism is not entirely lost, but the. autonomous increase in red cells is not due to raised levels oferythropoietin. In uncomplicated secondary polycythaemia only red cell proliferation is involved and this results from an increase in erythropoietin production. The latter may be a physiological response to a disorder that causes hypoxia, the known trigger for erythropoietin secretion. Alternatively it may be an inappropriate secretory response by a tumour or in certain rare familial conditions. However the practical classification of the polycythaemias has come to rely on other criteria. A scheme in common use is that of the American Polycythaemia Vera Study Group (Berlin 1975) .Given that the red cell mass is raised, a normal arterial oxygen saturation and the presence of splenomegaly is needed to make the diagnosis of primary polycythaemia. In the minority (about 30%) of patients suspected of this condition but without an enlarged spleen, evidence of white cell and platelet proliferation is required. If the oxygen saturation is low or the other essential criteria are lacking a search for secondary causes must follow.
Whilst an erythropoietin assay is part of the logical investigation of the polycythaemias, problems associated with the whole animal reference method (Cotes & Bangham 1961 ) have prevented it from coming into general use. The in vitro fetal mouse-liver-cell assay as described by Dunn & Napier (1975) has the advantage of economy in time and materials. In addition, there is an apparent increase in sensitivity though the specificity is still under question. The former is likely to be due in part to the measurement of the desialated hormone, which is rapidly destroyed in the whole animal assay. Having previously established a normal range, it was decided to estimate the serum erythropoietic stimulating factor as determined by this method in patients with primary and secondary polycythaemia.
Methods
Serum was obtained from 48 patients with an increased red cell mass, who fulfilled the criteria for primary polycythaemia laid down by the American group (Berlin 19, 75 ). Sera were also tested from 6 patients with low arterial oxygen saturation and 6 patients with tumAAAurJ 1 having a raised red cell mass. The sera were stored at below O°C. The assay f~.1l oWs~~. '..... that described by Dunn & Napier (1975) , in which cells obtained from 14.day'fetnf uluu~Rveis' are incubated for 24 hours with the material for testing. 59Feis added to the cultures and after a further period of 4 hours the radioactive iron is counted in the haem extracted from the cells. The sera are heat treated at 56°C for 30 minutes in order to destroy inhibitors. Human transferrin is added to the incubation mixture to provide an excess of unbound carrier protein.
Results
The normal range for this assay in this series has been found to be 0.09-0.28 u/ml.
Of the 48 patients considered to have primary polycythaemia, 36 fell into the normal range and 9 were below normal being undetectable. Of the 3 cases with high values, after further examination one was found to have a renal cyst and the second was considered to have inappropriate secretion of erythropoietin due to an unknown cause. However, the third case, apart from lacking splenomegaly, still fitted into the category of primary disease. Five of the 6 hypoxic patients had raised erythropoietin levels. Two of the sera from patients with renal tumours had increased activity. In one case a tumour extract also showed high levels. A tumour extract was positive in one of the cases with a normal serum level. Similarly raised levels were found in a uterine fibroid but not in the serum. An extract from a bronchogenic carcinoma had no activity and the serum level was undetectable. This patient was subsequently reclassified as having primary polycythaemia.
Discussion
The results in primary polycythaemia show a pattern similar to that reported using the whole animal assay. However, though some are undetectable the results in the normal range are higher than might be expected. This may be due to increased sensitivity of the assay or interference by other active agents. The hypoxic and tumour results also conform to previous whole animal assay results.
In practical terms these results suggest that where a diagnosis of primary polycythaemia is based on all the recognized criteria, an erythropoietin assay is superfluous. In difficult cases lacking splenomegaly, general myeloid hyperplasia or with a reduced oxygen saturation, a raised level will indicate the need for further investigations. However a normal level, though compatible with the primary disease, does not exclude a tumour or hypoxic cause of polycythaemia. These normal results could be due to the erythropoietin mechanism being switched offfollowing the rise in circulating haemoglobin. Further work is needed to determine whether the degree of response to a further stimulus to erythropoiesis such as venesection or cobalt could differentiate between these primary and secondary cases.
